Welcome to the TLDR Biotech newsletter!

TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Business Development

Boehringer Ingelheim pays OSE Immunotherapeutics €38.8M ($42 million) for pre-clinical asset
Antibody antagonist, cancer - Read more

Click Therapeutics clicks “buy” on assets of defunct Better Therapeutics
Digital therapeutics, obesity, diabetes - Read more

THE GOOD
Clinical Trials

Rezolute posts rezolutely positive mid-Ph2 data, boosting stock
Small molecule, eye disease, edema - Read more

Crinetics’ early share of positive mid-Ph2 data
Small molecule, congenital adrenal hyperplasia, rare disease - Read more

Sumitomo Pharma and Japan’s National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) begin Ph1 universal influenza vaccine trial
Flu vaccine - Read more

THE GOOD
Company Launches

SixPeaks Bio launches with up to $110M, aims to cut fat but keep muscle - while AstraZeneca waits in the wings
Antibody, obesity, weight loss - Read more

THE GOOD
Criminal Acts

MilliporeSigma foils a multimillion-dollar biochemical export scheme
Biochemical product, wire fraud - Read more

THE GOOD
Fundraises

En Carta Diagnostics €1.5M ($1.6M) Pre-Seed fundraise
Diagnostics, point-of-case, Lyme disease - Read more

Captain T Cell €8.5M ($9.2M) Seed fundraise
Cell therapy, TCR-T, cancer, solid tumors - Read more

Nanopath $4M in federal funding
Diagnostics, molecular testing, women’s health - Read more

Vaxess Technologies $12M raise
Medical device, drug delivery - Read more

PolarityTE $22.5M raise
Regenerative tissue, diabetic foot ulcers - Read more

NeoPhore undisclosed Series B extension
Small molecule, neoantigen, cancer - Read more

THE GOOD
Investments

Incyte Corporations plans home-state (Delaware) expansion
Small molecule, JAK inhibitors - Read more

Asymchem takes a bite from Pfizer’s facility sandwich, takes over site
Small molecule, API, manufacturing - Read more

Daiichi Sankyo plots expansions on both sides of the pond
Research & development - Read more [Paywall]

SPONSORED
Looking to leave the lab and get into sales?

One of the biggest hurdles to overcome in this job market is experience - and the next best thing you can do is get certified in life sciences sales skills.

Succession is running a 4-week “Welcome to Sales Accelerator” to give you the skills you need and help you land your first sales role. Ready to launch your life science sales career? (Spots are filling up for the June cohort.)

Use discount code WELCOMETOSALESTLDR for $100 off!

THE GOOD
IPOs

Tempus AI readies IPO bid
Diagnostics, AI, precision medicine - Read more

THE GOOD
Mergers & Acquisitions

Merck KGaA to buy Mirus Bio for $600M
Viral vector manufacturing - Read more

Biogen buys Hi-Bio for $1.15B upfront, $650M biobucks
Monoclonal antibody, immune-mediated indications - Read more

THE GOOD
Partnerships

AGC Biologics and BioConnection partner on end-to-end biopharma development
CDMO, manufacturing, fill-finish - Read more

THE GOOD
Patient Access

Bristol Myers Squibb maps expanded low- and middle-income country access to therapeutics
LMIC, therapeutic equity - Read more 

THE GOOD
Politics & Policy

Drugmakers score win in 340B discount program limitations case - Read more [Paywall]

THE GOOD
Product Launches

Labcorp’s new preeclampsia risk blood test
Preeclampsia, diagnostic test - Read more

THE GOOD
Regulatory

FDA discusses rare disease regulatory flexibility
Rare disease, approvals - Read more [Paywall]

THE BAD
Clinical Trials

Ph3 failure means Otsuka ditches Alzheimer’s med
Small molecule, Alzheimer’s Agitation - Read more

THE BAD
Company Shutdown

Cue Health shuts down
Covid-19, diagnostic testing - Read more

THE BAD
Strategic Plans

Pfizer tacks on another $1.5B in cuts
Cost-cutting, vaccine - Read more

Evotec shutters gene therapy division
Gene therapy, viral vector, drug development - Read more

THE UGLY
Accidents & Natural Disasters

Novo Nordisk suffers another fire, office building “unsaveable” - Read more

THE UGLY
Approvals and Labels

Novo Nordisk’s once weekly insulin’s hypoglycemia risk has FDA concerned
Diabetes, insulin, hypoglycemia - Read more [Paywall]

THE UGLY
Lawsuits

Henrietta Lacks family lawsuit against Ultragenyx moves forward
HeLa cells - Read more

THE UGLY
Politics and Policy

As BIOSECURE looms, House committee has domestic manufacturing “check up” with the FDA - Read more [Paywall]

THE UGLY
Research

New research provides more evidence linking talc powder and ovarian cancer - much to J&J’s likely chagrin
Talc powder, ovarian cancer - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 150+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.